Engineering Polymeric Nanosystems against Oral Diseases

Abstract

Nanotechnology and nanoparticles (NPs) are at the forefront of modern research, particularly in the case of healthcare therapeutic applications. Polymeric NPs, specifically, hold high promise for these purposes, including towards oral diseases. Careful optimisation of the production of polymeric NPs, however, is required to generate a product which can be easily translated from a laboratory environment to the actual clinical usage. Indeed, considerations such as biocompatibility, biodistribution, and biodegradability are paramount. Moreover, a pre-clinical assessment in adequate in vitro, ex vivo or in vivo model is also required. Last but not least, considerations for the scale-up are also important, together with an appropriate clinical testing pathway. This review aims to eviscerate the above topics, sourcing at examples from the recent literature to put in context the current most burdening oral diseases and the most promising polymeric NPs which would be suitable against them.

Simulate the Dynamic Interactions Across Nutritional Supplements, the Polybiome, and the Biochemical Approach Dependent on Patient-Derived Gastrointestinal Knowledge

“…Even while recent algorithms have demonstrated that there are considerable connections between the human intestinal microbiota and colonic illnesses, very little can be mentioned regarding how the metabolic activities and gene mutations of the microbial community impact colon tissue growth. [224]. This is still the case.…”

Biodegradable and Sustainable Synthetic Antibodies—A Perspective

“…The expression “molecular recognition” has seen increased use since the early 1980s, specifically indicating a group of phenomena driven by ad hoc physicochemical interactions (mainly noncovalent) [ 1 ]. These phenomena are critical for certain biological processes (e.g., ligand-receptor interactions), and a significant proportion of current research in chemistry, materials as well as pharmaceutical areas is indeed driven by the possibility of designing and tailoring specific molecular interactions suitable to be successfully employed in the desired applications [ 1 , 2 , 3 , 4 , 5 ].…”

Advances in Molecularly Imprinted Polymers as Drug Delivery Systems

“…Nevertheless, a burst release of drug is frequently observed in conventional polymeric vehicles, thus resulting in potentially severe consequences for the patients such as toxicity issues and undesirable side effects caused by temporarily high-drug dosage [5]. To date, although improved polymeric vehicles have been developed, some key knowledge gaps in terms of toxicity, physicochemical instability and lack of stimuli-responsiveness have been limitedly addressed, thus hindering practical applications [17][18][19]. On average, only one of the 5000 polymer-based DDSs that enters preclinical studies turns into an approved dosage form after~10 years (from the initial conception to the market approval) [20].…”